Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 4:09 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 2,669 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days

NCT05695352
View directory record Official record
Conditions
Pregnancy Prevention
Interventions
Levonorgestrel 1.5mg, Meloxicam 15 mg, Placebo
Drug · Other
Lead sponsor
InnovaGyn, Inc.
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 1, 2026, 4:09 PM EST
Completed Phase 2 Interventional Results available

A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration

NCT01124006
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Intradiscal rhGDF-5, Water for injection
Drug · Other
Lead sponsor
DePuy Spine
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
10
States / cities
Phoenix, Arizona • Santa Monica, California • Durango, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Nov 1, 2026, 4:09 PM EST
Recruiting Phase 3 Interventional

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

NCT07493304
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
REGN7508, Apixaban
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Hialeah, Florida • New York, New York • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 1, 2026, 4:09 PM EST
Terminated Not applicable Interventional

Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer

NCT05911243
View directory record Official record
Conditions
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Acupressure Therapy, Best Practice, Biospecimen Collection, Questionnaire Administration
Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Nov 1, 2026, 4:09 PM EST
Completed Not applicable Interventional Results available

The ConnectedCancerCare Pilot Study (CCC)

NCT03618017
View directory record Official record
Conditions
Early-stage Breast Cancer, Breast Cancer Female, Survivorship, Cancer Survivors, Transitional Care
Interventions
CCC website, Static care plan
Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
21 Years to 84 Years · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Nov 1, 2026, 4:09 PM EST
Completed Phase 2 Interventional Results available

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

NCT03166735
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
BI 1467335, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Coronado, California • La Jolla, California • La Mesa, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Nov 1, 2026, 4:09 PM EST
Active, not recruiting Phase 2 Interventional

Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis

NCT04767984
View directory record Official record
Conditions
Colorectal Carcinoma, Ulcerative Colitis
Interventions
Atorvastatin Calcium, Biopsy of Colon, Biospecimen Collection, Placebo Administration, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Nov 1, 2026, 4:09 PM EST
Completed Phase 2 Interventional Results available

Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.

NCT00766038
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Recombinant human Growth Hormone, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Bakersfield, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Nov 1, 2026, 4:09 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Audio and Video Brochures for Increasing Colorectal Cancer Screening Among Adults Living in Appalachia

NCT05810714
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Best Practice, Fecal Immunochemical Test, Health Education, Scheduled Notification, Survey Administration
Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
50 Years to 64 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Nov 1, 2026, 4:09 PM EST
Completed Not applicable Interventional Results available

Efficacy of Cantharidin in Molluscum Contagiosum

NCT00667225
View directory record Official record
Conditions
Molluscum Contagiosum, Skin Disease
Interventions
cantharidin's vehicle, Cantharidin 0.7%
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
5 Years to 10 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Nov 1, 2026, 4:09 PM EST
Suspended Phase 2 Interventional

Reducing Frailty for Older Cancer Survivors Using Supplements II

NCT06068543
View directory record Official record
Conditions
Frailty, Inflammation
Interventions
Epigallocatechin-3-Gallate (EGCG), Microcrystalline cellulose (MCC), Ascorbic Acid (Vitamin C)
Drug · Dietary Supplement
Lead sponsor
University of Rochester
Other
Eligibility
65 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Nov 1, 2026, 4:09 PM EST
Completed Phase 2 Interventional

INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria

NCT01398423
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
Active Control, INV-144
Drug
Lead sponsor
InVasc Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Garden Grove, California • La Mesa, California • Northridge, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Nov 1, 2026, 4:09 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Ph I/II of Vitamin D on Bone Mineral Density & Markers of Bone Resorption

NCT00904423
View directory record Official record
Conditions
Breast Cancer, Bone Diseases
Interventions
Vitamin D
Drug
Lead sponsor
Mark Pegram
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Nov 1, 2026, 4:09 PM EST
Completed Phase 2 Interventional Results available

A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension

NCT00522925
View directory record Official record
Conditions
Hypertension
Interventions
PS433540, placebo
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Tempe, Arizona • Lincoln, California • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2011 · Synced Nov 1, 2026, 4:09 PM EST
Recruiting Phase 2 Interventional

The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer

NCT05422690
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
Induction Chemotherapy Triplet Therapy, Concurrent Y-90 treatment, Consolidation Doublet Therapy:
Drug · Radiation
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Nov 1, 2026, 4:09 PM EST
Completed Phase 2 Interventional Results available

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

NCT01643850
View directory record Official record
Conditions
Pigmented Villonodular Synovitis, PVNS, Giant Cell Tumor of the Tendon Sheath, GCCTS, Tenosynovial Giant Cell Tumor Localized or Diffused Type, GCTS
Interventions
MCS110, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Nov 1, 2026, 4:09 PM EST
Terminated Phase 3 Interventional Results available

Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer

NCT03839940
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Dexamethasone, Placebo, Questionnaire, Quality-of-Life Assessment, Everolimus
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
319
States / cities
Birmingham, Alabama • Kingman, Arizona • Fort Smith, Arkansas + 198 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Nov 1, 2026, 4:09 PM EST
Completed Phase 2 Interventional

A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

NCT05559580
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Avenciguat (BI 685509), Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Covina, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Nov 1, 2026, 4:09 PM EST
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome

NCT05307679
View directory record Official record
Conditions
Dup15q Syndrome
Interventions
Basmisanil, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 14 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Nov 1, 2026, 4:09 PM EST
Completed Phase 2 Interventional Results available

Oral DS107 in Moderate to Severe Atopic Dermatitis

NCT02211417
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Oral DS107, Placebo
Drug
Lead sponsor
Dignity Sciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
8
States / cities
Arlington Heights, Illinois • West Dundee, Illinois • Warren, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Nov 1, 2026, 4:09 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Ocular Surface Immune Response in Dry Eye Disease

NCT02042820
View directory record Official record
Conditions
Dry Eye Disease
Interventions
In vivo confocal microscopy (IVCM)
Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Nov 1, 2026, 4:09 PM EST
Completed Phase 2 Interventional Results available

Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers

NCT02706717
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Visbiome Extra Strength, Placebo
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Nov 1, 2026, 4:09 PM EST
Completed Phase 2 Interventional

PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery

NCT00276523
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
PEG-interferon alfa-2b, Conventional surgery, Neoadjuvant therapy
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Nov 1, 2026, 4:09 PM EST
Completed Phase 1Phase 2 Interventional

ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

NCT04431258
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
ABTL0812, Folfirinox, Placebo
Drug
Lead sponsor
Ability Pharmaceuticals SL
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Westwood, Kansas • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Nov 1, 2026, 4:09 PM EST